Literature DB >> 10233895

Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration.

F M van 't Hooft1, A Silveira, P Tornvall, A Iliadou, E Ehrenborg, P Eriksson, A Hamsten.   

Abstract

Recent studies have provided evidence for associations between common polymorphic markers in the coagulation factor VII (FVII) gene and plasma FVII levels. Here we describe two common, nonrelated, functional polymorphisms in the promoter region of the FVII gene, a G to T substitution at position -401 and a novel G to A substitution at position -402. Both polymorphisms strongly influence the binding properties of nuclear protein(s). The rare -401T allele is associated with a reduced basal rate of transcription of the FVII gene in human hepatoblastoma cells and with reduced plasma concentrations of total FVII (VIIag) and fully activated FVII molecules (VIIa). In contrast, the rare -402A allele confers increased transcriptional activity and is associated with increased plasma FVII levels. Together, the two polymorphisms explained 18% and 28% of the variation in VIIag and VIIa, respectively, in a group of 183 healthy, middle-aged men. It is concluded that these polymorphisms are important for the regulation of the plasma levels of FVII and that they are likely to be useful genetic markers to resolve the issue of whether a causal relationship exists between FVII levels and risk of coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233895

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Genotyping on a thermal gradient DNA chip.

Authors:  Tomoharu Kajiyama; Yuji Miyahara; Larry J Kricka; Peter Wilding; David J Graves; Saul Surrey; Paolo Fortina
Journal:  Genome Res       Date:  2003-03       Impact factor: 9.043

2.  Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers.

Authors:  Liat Mlynarsky; Idit Bejarano-Achache; Mordechai Muszkat; Yoseph Caraco
Journal:  Eur J Clin Pharmacol       Date:  2011-11-10       Impact factor: 2.953

3.  Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin.

Authors:  Mateus Fuchshuber-Moraes; Jamila A Perini; Dieter Rosskopf; Guilherme Suarez-Kurtz
Journal:  Eur J Clin Pharmacol       Date:  2009-04-23       Impact factor: 2.953

4.  Human F7 sequence is split into three deep clades that are related to FVII plasma levels.

Authors:  Maria Sabater-Lleal; José Manuel Soria; Jaume Bertranpetit; Laura Almasy; John Blangero; Jordi Fontcuberta; Francesc Calafell
Journal:  Hum Genet       Date:  2005-11-16       Impact factor: 4.132

Review 5.  Regulatory polymorphisms underlying complex disease traits.

Authors:  Julian C Knight
Journal:  J Mol Med (Berl)       Date:  2004-12-09       Impact factor: 4.599

6.  Association of ACE and FACTOR VII gene variability with the risk of coronary heart disease in north Indian population.

Authors:  R C Sobti; Nishi Maithil; Hitender Thakur; Yashpaul Sharma; K K Talwar
Journal:  Mol Cell Biochem       Date:  2010-04-03       Impact factor: 3.396

7.  Warfarin dose requirement in Turkish patients: the influences of patient characteristics and polymorphisms in CYP2C9, VKORC1 and factor VII.

Authors:  E Yildirim; K Erol; A Birdane
Journal:  Hippokratia       Date:  2014 Oct-Dec       Impact factor: 0.471

8.  Role of coagulation factor VII in pathogenesis of ischemic heart disease.

Authors:  Yu Hu; Danmei Xu; Chunyan Sun; Zhangbo Chu; Jin'e Zhen; Huafang Wang; Wenning Wei
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

9.  Population genetic and phylogenetic evidence for positive selection on regulatory mutations at the factor VII locus in humans.

Authors:  Matthew W Hahn; Matthew V Rockman; Nicole Soranzo; David B Goldstein; Gregory A Wray
Journal:  Genetics       Date:  2004-06       Impact factor: 4.562

10.  Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.

Authors:  Masako Ohno; Akiko Yamamoto; Ayumu Ono; Genta Miura; Masanobu Funamoto; Yasuhiko Takemoto; Kinya Otsu; Yasushi Kouno; Tomoko Tanabe; Yuiko Masunaga; Shinpei Nonen; Yasushi Fujio; Junichi Azuma
Journal:  Eur J Clin Pharmacol       Date:  2009-07-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.